<DOC>
	<DOCNO>NCT01303991</DOCNO>
	<brief_summary>The purpose study investigate safety feasibility Hexaminolevulinate base photodynamic therapy patient intermediate high-risk transitional cell carcinoma bladder .</brief_summary>
	<brief_title>Hexvix Photodynamic Therapy Patients With Bladder Cancer</brief_title>
	<detailed_description>Non-muscle invasive bladder cancer currently treat transurethral resection ( TURB ) and/or fulguration . However , recurrence progression rate follow endoscopic treatment visible lesion significant . To prevent recurrent progressive disease , adjuvant intravesical chemotherapy immunotherapy apply . There also increase interest new therapeutic strategy photodynamic therapy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Male female age 18 year give write informed consent . Patients intermediate highrisk superficial bladder cancer , define lowgrade early recurrence within 6 month local chemotherapy BCG , primary recurrent highgrade disease ( TaG3 , TaG3 CIS CIS alone ) patient primary T1G3 tumour free second resection . Patients muscle invasive tumour Patients bladder shrinkage Patients receive prior PDT bladder cancer History T1G3 disease indication cystectomy Patient porphyria Gross haematuria . ( Note : Gross haematuria define heavy bladder bleed result marked amount blood urine , may interfere PDT ) Patients receive BCG chemotherapy within three month prior Hexvix instillation , except single dose chemotherapy prevention seed resection Known allergy hexaminolevulinate similar compound Participation clinical study either concurrently within last 30 day Women childbearing potential . Conditions associate risk poor protocol compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>